<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24885569</article-id><article-id pub-id-type="pmc">4052798</article-id><article-id pub-id-type="publisher-id">1472-6882-14-171</article-id><article-id pub-id-type="doi">10.1186/1472-6882-14-171</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antiviral activity and possible mode of action of ellagic acid identified in <italic>Lagerstroemia speciosa</italic> leaves toward human rhinoviruses</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Park</surname><given-names>Sang Wook</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>swpark@daewonpharm.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Kwon</surname><given-names>Min Jung</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mamasgirl@daum.net</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Yoo</surname><given-names>Ji Young</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gustmd1173@snu.ac.kr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Choi</surname><given-names>Hwa-Jung</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>rerived@empas.com</email></contrib><contrib contrib-type="author" corresp="yes" id="A5"><name><surname>Ahn</surname><given-names>Young-Joon</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>yjahn@snu.ac.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Interdisciplinary Program in Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, Seoul 151-921, Republic of Korea</aff><aff id="I2"><label>2</label>Department of Agricultural Biotechnology, Seoul National University, Seoul 151-921, Republic of Korea</aff><aff id="I3"><label>3</label>Department of Infection Biology, Zoonosis Research Center, Wonkwang University School of Medicine, Iksan 570-749, Jeollabuk-do, Republic of Korea</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>26</day><month>5</month><year>2014</year></pub-date><volume>14</volume><fpage>171</fpage><lpage>171</lpage><history><date date-type="received"><day>10</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Park et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Park et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1472-6882/14/171"/><abstract><sec><title>Background</title><p>Human rhinoviruses (HRVs) are responsible for more than half of all cases of the common cold and cause billions of USD annually in medical visits and school and work absenteeism. An assessment was made of the cytotoxic and antiviral activities and possible mode of action of the tannin ellagic acid from the leaves of <italic>Lagerstroemia speciosa</italic> toward HeLa cells and three rhinoviruses, HRV-2, -3, and -4.</p></sec><sec><title>Methods</title><p>The antiviral property and mechanism of action of ellagic acid were evaluated using a sulforhodamine B assay and real-time reverse transcription-PCR (RT-PCR) with SYBR Green dye. Results were compared with those of the currently used broad-spectrum antiviral agent, ribavirin.</p></sec><sec><title>Results</title><p>As judged by 50% inhibitory concentration values, natural ellagic acid was 1.8, 2.3, and 2.2 times more toxic toward HRV-2 (38&#x000a0;&#x003bc;g/mL), HRV-3 (31&#x000a0;&#x003bc;g/mL), and HRV-4 (29&#x000a0;&#x003bc;g/mL) than ribavirin, respectively. The inhibition rate of preincubation with 50&#x000a0;&#x003bc;g/mL ellagic acid was 17%, whereas continuous presence of ellagic acid during infection led to a significant increase in the inhibition (70%). Treatment with 50&#x000a0;&#x003bc;g/mL ellagic acid considerably suppressed HRV-4 infection only when added just after the virus inoculation (0&#x000a0;h) (87% inhibition), but not before -1&#x000a0;h or after 1&#x000a0;h or later (&#x0003c;20% inhibition). These findings suggest that ellagic acid does not interact with the HRV-4 particles and may directly interact with the human cells in the early stage of HRV infections to protect the cells from the virus destruction. Furthermore, RT-PCR analysis revealed that 50&#x000a0;&#x003bc;g/mL ellagic acid strongly inhibited the RNA replication of HRV-4 in HeLa cells, suggesting that ellagic acid inhibits virus replication by targeting on cellular molecules, rather than virus molecules.</p></sec><sec><title>Conclusions</title><p>Global efforts to reduce the level of antibiotics justify further studies on <italic>L. speciosa</italic> leaf-derived materials containing ellagic acid as potential anti-HRV products or a lead molecule for the prevention or treatment of HRV infection.</p></sec></abstract><kwd-group><kwd>Human rhinovirus</kwd><kwd>Natural antiviral agent</kwd><kwd><italic>Lagerstroemia speciosa</italic></kwd><kwd>Ellagic acid</kwd><kwd>Tannin</kwd><kwd>Cytotoxicity</kwd><kwd>Selectivity</kwd><kwd>RNA replication</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Human rhinoviruses (HRVs) (Picornaviridae) are the most frequent cause of mild upper respiratory tract infection, or common cold. They are responsible for more than half of all cases of the common cold
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. HRVs are also associated with more severe diseases such as acute otitis media in children
[<xref ref-type="bibr" rid="B3">3</xref>] and sinusitis in adults
[<xref ref-type="bibr" rid="B4">4</xref>]. HRVs can also cause severe lower respiratory tract infections such as pneumonia
[<xref ref-type="bibr" rid="B5">5</xref>], wheezing
[<xref ref-type="bibr" rid="B6">6</xref>], bronchiolitis, and exacerbations of asthma and chronic obstructive pulmonary disease
[<xref ref-type="bibr" rid="B2">2</xref>] in infants and children as well as fatal pneumonia in elderly and immunocompromised adults
[<xref ref-type="bibr" rid="B7">7</xref>]. Although HRV-induced upper respiratory illness is often mild and self-limiting, the socioeconomic impact caused by medical visits and school and work absenteeism by HRV infection is considerable and the degree of inappropriate antibiotic use is significant
[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. More than 100 serotypes of HRV become an obstacle of development of a unifying vaccine
[<xref ref-type="bibr" rid="B10">10</xref>]. There is, therefore, a high need for the development of selective antiviral agents with novel target sites to establish an effective HRV management strategy and tactics because there are currently no approved antiviral therapies for the prevention or treatment of HRV infection
[<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Plants have been suggested as alternative sources for antiviral products largely because they constitute a potential source of bioactive secondary substances that have been perceived by the general public as relatively safe, with minimal impacts to human health, and often act at multiple and novel target sites
[<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Much effort has been focused on plants and their constituents as potential sources of commercial antiviral products for prevention or treatment of HRV infection. In the screening of plants for anti-HRV activity, a methanol extract from the leaves of Giant Crape-myrtle (called banaba in the Phillippines), <italic>Lagerstroemia speciosa</italic> (L.) Pers. (Lythraceae), was shown to have good antiviral activity toward HRV-4. Very little information has been done to consider potential use of <italic>L. speciosa</italic> to manage HRV, although the plant leaves possess antidiabetic and hypoglycemic
[<xref ref-type="bibr" rid="B15">15</xref>], antiobesity
[<xref ref-type="bibr" rid="B16">16</xref>], antioxidant
[<xref ref-type="bibr" rid="B17">17</xref>], antigout
[<xref ref-type="bibr" rid="B18">18</xref>], antiinflammatory
[<xref ref-type="bibr" rid="B19">19</xref>], and antibacterial activities
[<xref ref-type="bibr" rid="B20">20</xref>].</p><p>The aim of the study was to assess the cytotoxic and antiviral effects on HeLa cells and three HRV serotypes (HRV-2, HRV-3, and HRV-4) of the tannin ellagic acid from <italic>L. speciosa</italic> leaves, compared to commercial pure ellagic acid and ribavirin, a currently used broad-spectrum antiviral agent
[<xref ref-type="bibr" rid="B21">21</xref>]. The antiviral property and mechanisms of action of the constituent were elucidated using sulforhodamine B (SRB) assay and real-time reverse transcription-PCR with SYBR Green dye.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Instrumental analysis</title><p><sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in DMSO-<italic>d</italic><sub>6</sub> on a JNM-ECX 400 spectrometer (Jeol, Tokyo, Japan) at 400 and 100&#x000a0;MHz, respectively, using tetramethylsilane as an internal standard, and chemical shifts are given in &#x003b4; (ppm). UV spectra were obtained in methanol on a BioMate 5 spectrophotometer (Thermo Spectronic, Rochester, NY), Fourier transform infrared (FT-IR) spectra on a Nicolet Magna 550 series II spectrometer (Midac, Atlanta, GA), and mass spectra on a Jeol GSX 400 spectrometer. Silica gel 60 (0.063&#x02013;0.2&#x000a0;mm) (Merck, Darmstadt, Germany) was used for column chromatography. Merck precoated silica gel plates (Kieselgel 60&#x000a0;F<sub>254</sub>, 0.20&#x000a0;mm) were used for analytical thin-layer chromatography (TLC). A SCL-10 AVP high-performance liquid chromatograph (Shimadzu, Kyoto, Japan) was used for isolation of active principles.</p></sec></sec><sec sec-type="materials"><title>Materials</title><p>Commercially available pure ellagic acid (&#x02265;95% purity) and SRB were purchased from Sigma-Aldrich (St. Louis, MO). The antiviral agent ribavirin was supplied by Tokyo Chemical Industry (Tokyo). Anitbiotic-antimycotic and minimum essential medium (MEM) were purchased from Invitrogen (Grand Island, NY). Fetal bovine serum was supplied by PAA Laboratories (Etobicoke, Ontario, Canada). All of the other chemicals and reagents used in this study were of analytical grade quality and available commercially.</p><sec><title>Human rhinovirus serotypes and cell line</title><p>HeLa (ATCC CCL-2), a human epithelial adenocarcinoma cervix cell line, was purchased from the American Type Culture Collection (ATCC) (Manassas, VA). The cell line was maintained in MEM supplemented with 10% fetal bovine serum and 0.01% antibiotic-antimycotic in a humidified incubator at 37&#x000b0;C and 5% CO<sub>2</sub>. HRV-2 (ATCC VR-1112AS/GP), HRV-3 (ATCC VR-1113), and HRV-4 (ATCC VR-1114AS/GP) were purchased from ATCC. The three HRVs were propagated in HeLa cells at 37&#x000b0;C. Virus titers were determined by cytopathic effects (CPE) in HeLa cells and were expressed as 50% cell culture infective dose (CCID<sub>50</sub>) per mL as described previously
[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Plants</title><p>Air-dried leaves of <italic>L. speciosa</italic> were purchased from a local Giant Crape-myrtle farm in the Philippines. A certified botanical taxonomist was used to identify the plant. A voucher specimen (LS-1&#x000a0;L) was deposited in the Research Institute of Agriculture and Life Sciences, College of Agriculture and Life Sciences, Seoul National University.</p></sec><sec><title>Bioassay-guided fractionation and isolation</title><p>Air-dried leaves (2&#x000a0;kg) of <italic>L. speciosa</italic> were pulverized, extracted with methanol (2&#x02009;&#x000d7;&#x02009;10&#x000a0;L) at room temperature for 2&#x000a0;days, and filtered. The combined filtrate was concentrated to dryness by rotary evaporation at 40&#x000b0;C to yield 112&#x000a0;g of a dark greenish powder. The extract (100&#x000a0;g) was sequentially partitioned into hexane- (9.35&#x000a0;g), ethyl acetate- (14.4&#x000a0;g), butanol- (39.35&#x000a0;g), and water-soluble (36.9&#x000a0;g) portions for subsequent bioassay. The organic solvent-soluble portions were concentrated under vacuum at 40&#x000b0;C and water-soluble portion was concentrated at 50&#x000b0;C. For isolation of active principles, viral CPE inhibition assay described previously
[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>] toward HRV-4 in HeLa cell was used.</p><p>The ethyl acetate-soluble fraction (10&#x000a0;g) was most biologically active (Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>) and was chromatographed on a 70&#x02009;&#x000d7;&#x02009;5.5&#x000a0;cm silica gel (600&#x000a0;g) column by elution with a gradient of chloroform and methanol (100:0 (2&#x000a0;L), 99:1 (1&#x000a0;L), 95:5 (1&#x000a0;L), 90:10 (1&#x000a0;L), 80:20 (1&#x000a0;L), 70:30 (1&#x000a0;L), 60:40 (1&#x000a0;L), 50:50 (1&#x000a0;L), and 0:100 (2&#x000a0;L) by volume) to provide 19 fractions (each about 500&#x000a0;mL) (Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>). Column fractions were monitored by TLC on silica gel plates developed with chloroform and methanol (9:1 by volume) mobile phase. Fractions with similar <italic>R</italic><sub>f</sub> values on the TLC plates were pooled. Spots were detected by spraying with 10% sulfuric acid and then heating on a hot plate. Active fractions 13 to 15 (1.23&#x000a0;g) were pooled and separated into chloroform-soluble (474&#x000a0;mg) and -nonsoluble (756&#x000a0;mg) fractions. The active nonsoluble fraction was separated into methanol-soluble (330&#x000a0;mg) and -nonsoluble (426&#x000a0;mg) fractions. The active methanol-soluble fraction was separated by TLC plate developed with <italic>n</italic>-BuOH/HOAc/H<sub>2</sub>O (4:1:5 by volume) to give an active fraction (45&#x000a0;mg, <italic>R</italic><sub>f</sub>&#x02009;=&#x02009;0.12). For further separation of the constituents from the active fraction, a high-performance liquid chromatography was performed. The column was a 4&#x000a0;mm i.d. &#x000d7; 200&#x000a0;mm EC 200/4 Nucleodex alpha-PM (Macherey-Nagel, Easton, PA) using a mobile phase of methanol and water (9:1 by volume) at a flow rate of 1&#x000a0;mL/min. Chromatographic separations were monitored using a UV detector at 340&#x000a0;nm. Finally, an active principle (35&#x000a0;mg) was isolated at a retention time of 2.61&#x000a0;min. The isolate was obtained as green amorphous powder and identified by instrumental analyses, including MS and NMR. The mass spectrum exhibited a molecular ion at <italic>m/z</italic> 302 [M]<sup>+</sup> and IR absorption at 3380, 1720, and 1690&#x02013;1610&#x000a0;cm<sup>-1</sup> indicates the presence of phenolic hydroxyl, &#x003b1;-pyrone C&#x02009;=&#x02009;O, and benzonoid C&#x02009;=&#x02009;C groups, respectively. This compound (1) was thus identified as ellagic acid (2,3,7,8-tetrahydroxy-chromeno[5,4,3-cde] chromene-5,10-dione) (Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>). The interpretations of proton and carbon signals were largely consistent with those of Nawwar and Souleman
[<xref ref-type="bibr" rid="B24">24</xref>]. Ellagic acid was identified on the basis of the following evidence: green amorphous power. UV (MeOH) &#x003bb;<sub>max</sub> nm: 255, 360. FT-IR: <italic>&#x003bd;</italic><sub>max</sub> cm<sup>-1</sup>: 3380, 1720, 1690, 1610. EI-MS (70&#x000a0;eV) <italic>m/z</italic> (% relative intensity): 302 [M]<sup>+</sup> (12), 278 (37), 256 (41), 105 (64), 57 (100). <sup>1</sup>H NMR (DMSO-<italic>d</italic><sub>6</sub>, 400&#x000a0;MHz): &#x003b4; 7.47 (2H, s, ArH). <sup>13</sup>C NMR (DMSO-<italic>d</italic><sub>6</sub>, 100&#x000a0;MHz): &#x003b4; 107.7, 110.2, 112.2, 136.2, 139.5, 147.9, 159.0.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>Cytotoxicity and antiviral activity of fractions obtained from the solvent partitionings of the methanol extract of </bold><bold>
<italic>L. speciosa </italic>
</bold><bold>leaves toward human rhinovirus-4 in HeLa cells using sulforhodamine B bioassay</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Test material</bold></th><th align="left"><bold>CC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL)</bold></th><th align="left"><bold>IC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL) (&#x000b1;SD)</bold></th><th align="left"><bold>TI</bold><sup>
<bold>a</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Methanol extract<hr/></td><td align="left" valign="bottom">1036<hr/></td><td align="left" valign="bottom">82&#x02009;&#x000b1;&#x02009;1.8<sup>d</sup><hr/></td><td align="left" valign="bottom">12.6<hr/></td></tr><tr><td align="left" valign="bottom">Hexane-soluble fraction<hr/></td><td align="left" valign="bottom">1074<hr/></td><td align="left" valign="bottom">777&#x02009;&#x000b1;&#x02009;5.8<sup>b</sup><hr/></td><td align="left" valign="bottom">1.4<hr/></td></tr><tr><td align="left" valign="bottom">Ethyl acetate-soluble fraction<hr/></td><td align="left" valign="bottom">1675<hr/></td><td align="left" valign="bottom">71&#x02009;&#x000b1;&#x02009;1.0<sup>d</sup><hr/></td><td align="left" valign="bottom">23.5<hr/></td></tr><tr><td align="left" valign="bottom">Butanol-soluble fraction<hr/></td><td align="left" valign="bottom">1260<hr/></td><td align="left" valign="bottom">881&#x02009;&#x000b1;&#x02009;8.7<sup>a</sup><hr/></td><td align="left" valign="bottom">1.4<hr/></td></tr><tr><td align="left">Water-soluble fraction</td><td align="left">1409</td><td align="left">607&#x02009;&#x000b1;&#x02009;3.5<sup>c</sup></td><td align="left">2.3</td></tr></tbody></table><table-wrap-foot><p>Means within a column followed by the same letter are not significantly different (<italic>P</italic>&#x02009;=&#x02009;0.05, Bonferroni method).</p><p><sup>a</sup>Therapeutic index&#x02009;=&#x02009;CC<sub>50</sub>/IC<sub>50</sub>.</p></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Isolation procedures of anti-HRV principle.</bold> The <italic>Lagerstroemia speciosa</italic> leaf methanol extract was sequentially partitioned into hexane-, ethyl acetate-, butanol-, and water-soluble portions. For isolation of active principles from the ethyl acetate-soluble fraction, viral cytopathic inhibition assay toward HRV-4 in HeLa cell was used.</p></caption><graphic xlink:href="1472-6882-14-171-1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Structure of ellagic acid.</bold> The chemical formula is C<sub>14</sub>H<sub>6</sub>O<sub>8</sub>; the molecular weight is 302.197&#x000a0;g/mol.</p></caption><graphic xlink:href="1472-6882-14-171-2"/></fig></sec><sec><title>Antiviral assay</title><p>The antiviral activity of <italic>L. speciosa</italic> leaf-derived materials toward three HRVs tested was evaluated by the SRB method using CPE reduction
[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. In brief, HeLa cells were seeded onto a 96-well microtiter plate at a concentration of 3&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells per well for 1&#x000a0;day. The culture medium was then removed, and the plates were washed with 1&#x02009;&#x000d7;&#x02009;phosphate-buffered saline (PBS) (pH&#x000a0;7.3). Subsequently, 90&#x000a0;&#x003bc;L of diluted virus suspension containing CCID<sub>50</sub> of the virus stock was added to produce an appropriate CPE within 2&#x000a0;days after infection, followed by the addition of 10&#x000a0;&#x003bc;L of MEM supplemented with 30&#x000a0;mM MgCl<sub>2</sub> containing four to five concentrations of each test material in 0.1% dimethylsulfoxide (DMSO), based on the preliminary test results. The culture plates were incubated at 37&#x000b0;C and 5% CO<sub>2</sub> for 2&#x000a0;days. After washing with 1&#x02009;&#x000d7;&#x02009;PBS, 100&#x000a0;&#x003bc;L of 70% cold acetone were added to each well and left for 30&#x000a0;min at -20&#x000b0;C. After acetone solution was removed, the plates were left in a dry oven. A volume of 100&#x000a0;&#x003bc;L of 0.057% (w/v) SRB in 1% acetic acid solution was added to each well and left at room temperature for 30&#x000a0;min. Unbound SRB was removed and the plates were washed five times with 1% acetic acid before drying and were then left in a dry oven for 1&#x000a0;day. Bound SRB was solubilized with 100&#x000a0;&#x003bc;L of 10&#x000a0;mM unbuffered Tris-base solution and plates were left on a table for 30&#x000a0;min. Absorbance was read at 562&#x000a0;nm by using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA) with a reference absorbance at 620&#x000a0;nm. Ribavirin served as a positive control and was similarly prepared. Negative controls consisted of the DMSO solution. Viral inhibition rate (%) was calculated using the following formula
[<xref ref-type="bibr" rid="B25">25</xref>]: (<italic>OD</italic><sub>tV</sub> &#x02013; <italic>OD</italic><sub>cV</sub>)/(<italic>OD</italic><sub>cd</sub> &#x02013; <italic>OD</italic><sub>cV</sub>)&#x02009;&#x000d7;&#x02009;100, where <italic>OD</italic><sub>tV</sub> is the optical density measured with a given concentration of the test material in HRV infected cells; <italic>OD</italic><sub>cV</sub> is the optical density measured for the control untreated HRV infected cells; <italic>OD</italic><sub>cd</sub> is the optical density measured for the control untreated HRV uninfected cells.</p></sec><sec><title>Cytotoxicity assay</title><p>HeLa cells were seeded onto a 96-well microtiter plate as stated previously. The culture medium was removed and the plates were replaced with media containing different concentrations of the test materials in DMSO, based on the preliminary test results. After incubation at 37&#x000b0;C with 5% CO<sub>2</sub> for 2&#x000a0;days, the cytotoxicity of the test materials to HeLa cells was evaluated using a SRB assay
[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>] as stated previously.</p></sec><sec><title>Infectivity of HRV particles</title><p>The effects of ellagic acid and ribavirin on the infectivity of HRV-4 particles were evaluated as described previously by Choi et al.
[<xref ref-type="bibr" rid="B23">23</xref>]. Approximately twofold quantities of the IC<sub>50</sub> values of each test compound were applied. HRV-4 was preincubated with 50&#x000a0;&#x003bc;g/mL ellagic acid or 100&#x000a0;&#x003bc;g/mL ribavirin for 1&#x000a0;h at 4&#x000b0;C. Monolayers of HeLa cells were infected with the pretreated or untreated HRV-4 for 1&#x000a0;h at 37&#x000b0;C. Unbound virus was removed by washing the wells with 2&#x02009;&#x000d7;&#x02009;PBS, and then cells were incubated in fresh medium supplemented with or without test compound at 37&#x000b0;C. After 2&#x000a0;days, SRB test and antiviral activity were carried out as stated previously.</p></sec><sec><title>Time course</title><p>The time-of-addition effects of ellagic acid were tested according to the method of Choi et al.
[<xref ref-type="bibr" rid="B23">23</xref>]. In brief, monolayers of HeLa cells were seeded onto a 96-well microtiter plate as stated previously. After washing with 1&#x02009;&#x000d7;&#x02009;PBS, 50&#x000a0;&#x003bc;g/mL ellagic acid were added onto the culture cells at before (-1&#x000a0;h), during (0&#x000a0;h), or after (1, 2, 4, and 6&#x000a0;h) HRV-4 infection at 37&#x000b0;C. Ribavirin served as a positive control and was similarly prepared. After 2&#x000a0;days, SRB test and antiviral activity were carried out as stated previously.</p></sec><sec><title>Reverse transcription-PCR analysis</title><p>To evaluate the level of gene expression, quantitative real-time reverse transcription-PCR (RT-PCR) with SYBR Green dye was performed. HRV-4 infected and noninfected cultures of HeLa cells grown in Corning 25&#x000a0;cm<sup>2</sup> cell culture flasks (Corning, NY) were treated with 50&#x000a0;&#x003bc;g/mL ellagic acid or 100&#x000a0;&#x003bc;g/mL ribavirin. After incubation at 37&#x000b0;C and 5% CO<sub>2</sub> for 2&#x000a0;days, total RNA was extracted from the culture cells using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s instructions. Contaminated genomic DNA was removed using RQ1 RNase-free DNase (Promega, Madison, WI). Complementary DNA was synthesized using 1&#x000a0;&#x003bc;g total RNA through a reverse transcription reaction using the SuperScript First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA). Quantitative RT-PCR was performed in 96-well plates using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster, CA). Each reaction mixture consisted of 10&#x000a0;&#x003bc;L of Maxima SYBR Green/ROX qPCR Master Mix (2&#x000d7;) (Thermo Scientific, Foster, CA), 2&#x000a0;&#x003bc;L of forward and reverse primers (5 pmol each), 1&#x000a0;&#x003bc;L of complementary DNA (8&#x000a0;ng), and 7&#x000a0;&#x003bc;L of double-distilled water in a final volume of 20&#x000a0;&#x003bc;L. Oligonucleotide PCR primers for &#x003b2;2-microglobulin (assay ID AF072097) and HRV-4 (assay ID DQ473490.1) were purchased from Applied Biosystems. The PCR conditions were as follows: 50&#x000b0;C for 2&#x000a0;min, 95&#x000b0;C for 10&#x000a0;min, and then 50&#x000a0;cycles of 95&#x000b0;C for 15&#x000a0;s and 60&#x000b0;C for 30&#x000a0;s. mRNA expression level of target gene was normalized to mRNA expression level for the housekeeping gene &#x003b2;2-microglobulin and analyzed by the 2<sup>&#x02013;&#x00394;&#x00394;<italic>C</italic>T</sup> method using StepOne Software v2.1 and DataAssist Software (Applied Biosystems).</p></sec><sec><title>Data analysis</title><p>Cytotoxicity was expressed as 50% cytotoxic concentration (CC<sub>50</sub>) of the compound that reduced the viability of cells to 50% of the control. Fifty percent inhibitory concentration (IC<sub>50</sub>) was defined as the compound concentration required to reducing the viral CPE to 50% of the control. The CC<sub>50</sub> and IC<sub>50</sub> values were calculated using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Therapeutic index was determined as the ratio of CC<sub>50</sub> to IC<sub>50</sub>. Results were expressed as mean&#x02009;&#x000b1;&#x02009;SD of triplicate samples of three independent experiments. Statistical analyses were carried out using SAS 9.13 program (SAS Institute, Cary, NC). Data from two groups were analyzed by a Student&#x02019;s <italic>t</italic>-test, and multiple groups were analyzed by a one-way analysis of variance and Bonferroni multiple comparison test.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Anti-HRV activity of test compounds</title><p>The antiviral activities of natural ellagic acid, commercial pure ellagic acid, and ribavirin were significantly different from each other toward HRV-2 (<italic>F</italic>&#x02009;=&#x02009;72.17; df&#x02009;=&#x02009;2, 6; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), HRV-3 (<italic>F</italic>&#x02009;=&#x02009;134.26; df&#x02009;=&#x02009;2, 6; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), and HRV-4 (<italic>F</italic>&#x02009;=&#x02009;81.32; df&#x02009;=&#x02009;2, 6; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) (Table&#x000a0;
<xref ref-type="table" rid="T2">2</xref>). Based on IC<sub>50</sub> values, the natural ellagic acid and pure ellagic acid did not differ significantly in the antiviral activity toward three HRVs, indicating that the activity of the methanol-extracted ellagic acid is purely due to ellagic acid. Natural ellagic acid was 1.8, 2.3, and 2.2 times more toxic toward HRV-2 (IC<sub>50</sub>, 38&#x000a0;&#x003bc;g/mL), HRV-3 (31&#x000a0;&#x003bc;g/mL), and HRV-4 (29&#x000a0;&#x003bc;g/mL) than ribavirin, respectively. CC<sub>50</sub> of ellagic acid and ribavirin was &#x0003e;100&#x000a0;&#x003bc;g/mL toward HeLa cells in a SRB assay.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Cytotoxicity and antiviral activity of ellagic acid and antiviral agent ribavirin toward human rhinovirus-4 in HeLa cells using sulforhodamine B bioassay</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Compound</bold><hr/></th><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="left" valign="bottom"><bold>HRV-2</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>HRV-3</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>HRV-4</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left"><bold>CC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL)</bold></th><th align="left"><bold>IC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL) (&#x000b1;SD)</bold></th><th align="left"><bold>TI</bold><sup>
<bold>a</bold>
</sup></th><th align="left"><bold>IC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL) (&#x000b1;SD)</bold></th><th align="left"><bold>TI</bold><sup>
<bold>a</bold>
</sup></th><th align="left"><bold>IC</bold><sub>
<bold>50 </bold>
</sub><bold>(&#x003bc;g/mL) (&#x000b1;SD)</bold></th><th align="left"><bold>TI</bold><sup>
<bold>a</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Natural EA<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;100<hr/></td><td align="left" valign="bottom">38&#x02009;&#x000b1;&#x02009;3.2<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;2.6<hr/></td><td align="left" valign="bottom">31&#x02009;&#x000b1;&#x02009;5.2<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;3.2<hr/></td><td align="left" valign="bottom">29&#x02009;&#x000b1;&#x02009;2.5<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;3.4<hr/></td></tr><tr><td align="left" valign="bottom">Pure EA<hr/></td><td align="left" valign="bottom">&#x0003e;100<hr/></td><td align="left" valign="bottom">41&#x02009;&#x000b1;&#x02009;1.1<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;2.4<hr/></td><td align="left" valign="bottom">30&#x02009;&#x000b1;&#x02009;2.4<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;3.3<hr/></td><td align="left" valign="bottom">29&#x02009;&#x000b1;&#x02009;1.7<sup>b</sup><hr/></td><td align="left" valign="bottom">&#x0003e;3.4<hr/></td></tr><tr><td align="left">Ribavirin</td><td align="left">&#x0003e;100</td><td align="left">70&#x02009;&#x000b1;&#x02009;4.9<sup>a</sup></td><td align="left">&#x0003e;1.4</td><td align="left">71&#x02009;&#x000b1;&#x02009;0.5<sup>a</sup></td><td align="left">&#x0003e;1.4</td><td align="left">63&#x02009;&#x000b1;&#x02009;5.6<sup>a</sup></td><td align="left">&#x0003e;1.6</td></tr></tbody></table><table-wrap-foot><p>Means within a column followed by the same letter are not significantly different (<italic>P</italic>&#x02009;=&#x02009;0.05, Bonferroni method).</p><p><sup>a</sup>Therapeutic index&#x02009;=&#x02009;CC<sub>50</sub>/IC<sub>50</sub>.</p><p><sup>b</sup>Ellagic acid.</p></table-wrap-foot></table-wrap></sec><sec><title>Effect on the infectivity of HRV particles</title><p>The effects of ellagic acid and ribavirin on the infectivity of HRV-4 particles were likewise examined (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>). The inhibition rates of preincubation with 50&#x000a0;&#x003bc;g/mL ellagic acid and 100&#x000a0;&#x003bc;g/mL ribavirin were 17 and 5.7%, respectively. Continuous presence of ellagic acid and ribavirin during infection led to a significant increase in the inhibition rate (70 and 65.7%).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Effect on the infectivity of HRV-4 particles.</bold> Approximately twofold quantities of the IC<sub>50</sub> values of ellagic acid (EA) and ribavirin (RN) were applied. Human rhinovirus-4 (HRV-4) particles were incubated with 50&#x000a0;&#x003bc;g/mL EA and 100&#x000a0;&#x003bc;g/mL RN for 1&#x000a0;h at 4&#x000b0;C. Afterwards, HeLa cells were incubated with treated or untreated virus for 1&#x000a0;h at 37&#x000b0;C. Unbound virus was removed by washing the wells, and infection was continued by cultivating cells in fresh medium with or without test compound at 37&#x000b0;C. After 2&#x000a0;days, inhibition was evaluated by SRB method and expressed as the inhibition rate. Each bar represents the mean&#x02009;&#x000b1;&#x02009;SD of triplicate samples of three independent experiments. <sup>***</sup>Significant at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, according to a Student&#x02019;s <italic>t</italic>-test.</p></caption><graphic xlink:href="1472-6882-14-171-3"/></fig></sec><sec><title>Time course of compound addition</title><p>To investigate the mode of action of ellagic acid and ribavirin, time course of the inhibition of these compounds at different periods (before, during, and after) of HRV-4 infection was likewise investigated (Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>). Treatment with 50&#x000a0;&#x003bc;g/mL ellagic acid considerably suppressed HRV infection only when added just after the virus inoculation (0&#x000a0;h) (87% inhibition). The inhibition rate of ellagic acid declined to 20% or less when added at either prior (-1&#x000a0;h) or post (1, 2, 4, and 6&#x000a0;h) infection. However, the inhibitory effect of 100&#x000a0;&#x003bc;g/mL ribavirin on HRV-4 infection occurred between 0 and 6&#x000a0;h.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Time-of-addition effect on HRV-4 replication in HeLa cells.</bold> Approximately twofold quantities of the IC<sub>50</sub> values of ellagic acid (EA) and ribavirin (RN) were applied. The 50&#x000a0;&#x003bc;g/mL EA and 100&#x000a0;&#x003bc;g/mL RN were added at various times preinfection (-1&#x000a0;h), coinfection (0&#x000a0;h), or postinfection (1, 2, 4, and 6&#x000a0;h) of human rhinovirus-4 (HRV-4) to HeLa cells at 37&#x000b0;C. After 2&#x000a0;days, inhibition was evaluated by SRB method and expressed as the inhibition rate. Each bar represents the mean&#x02009;&#x000b1;&#x02009;SD of triplicate samples of three independent experiments.</p></caption><graphic xlink:href="1472-6882-14-171-4"/></fig></sec><sec><title>Effect on the level of HRV replication</title><p>The RNA replication level of HRV-4 in HeLa cells was remarkably inhibited in the cell cultures treated with 50&#x000a0;&#x003bc;g/mL ellagic acid (Figure&#x000a0;
<xref ref-type="fig" rid="F5">5</xref>). The RNA replication level of HRV-4 was reduced by 5 fold, compared to the level in the cell cultures without ellagic acid.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Effect on replication level of HRV-4.</bold> The RNA replication level of human rhinovirus (HRV-4) was detected by real-time reverse transcription-PCR with SYBR Green dye in HeLa cells 2&#x000a0;days after infection in the presence of 50&#x000a0;&#x003bc;g/mL ellagic acid (EA). HRV RNA expressions were normalized to the constitutive expression of mRNA of the housekeeping gene &#x003b2;2-microglobulin (B2M) and analyzed by the 2<sup>&#x02013;&#x02206;&#x02206;<italic>C</italic>T</sup> method using StepOne Software v2.1 and DataAssist Software. Each bar represents the mean&#x02009;&#x000b1;&#x02009;SD of duplicate samples of three independent experiments. <sup>***</sup>Significant at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, according to a Student&#x02019;s <italic>t</italic>-test.</p></caption><graphic xlink:href="1472-6882-14-171-5"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The current <italic>in vitro</italic> study indicates that materials derived from <italic>L. speciosa</italic> leaves exhibited antiviral activity and selectivity toward three rhinoviruses HRV-2, HRV-3, and HRV-4. The plant grows widely in tropical countries, including the Philippines, India, Malaysia, China, and Australia and is a popular folk medicine in Southeast Asia. <italic>L. speciosa</italic> leaves contain acetal, alkaloids, sterols, tannins, and triterpenoids
[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Excellent antidiabetic properties of a standardized extract from <italic>L. speciosa</italic> leaves have been well noted
[<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>].</p><p>Various compounds, including phenolics, terpenoids, and alkaloids, exist in plants, and jointly or independently they contribute to antiviral efficacy
[<xref ref-type="bibr" rid="B14">14</xref>]. Many plants and their constituents manifest antiviral activity toward different viruses
[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B30">30</xref>] and have been proposed as alternatives to conventional antiviral drugs. Anti-HRV constituents derived from plants include alkaloids (e.g., arborinine and (<italic>S</italic>)-ribalinine, IC<sub>50</sub> 3.19 and 82.95&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B31">31</xref>]; glaucine, IC<sub>50</sub> 22&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B32">32</xref>]), coumarins (e.g., 6,7,8-trimethoxycoumarin and daphnoretin methyl ether, IC<sub>50</sub> 11.98 and 97.08&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B31">31</xref>]; farnesiferol B and C, IC<sub>50</sub>&#x02009;&#x02248;&#x02009;2.61&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B33">33</xref>]), flavonoids (e.g., 4&#x02032;,5-dihydroxy-3&#x02032;,3,7-trimethoxyflavone, IC<sub>50</sub> 0.29&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B34">34</xref>]; 3-methylquercetin and three related compounds, effective concentration 15.8&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B35">35</xref>]; chrysosplenol D and others, minimum effective dose 0.22&#x02013;33.3&#x000a0;&#x003bc;M)
[<xref ref-type="bibr" rid="B36">36</xref>]; chrysosplenol C, IC<sub>50</sub> 0.75&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B37">37</xref>]), terpenoids (e.g., 3-<italic>O</italic>-<italic>trans</italic>-caffeoyltormentic acid, IC<sub>50</sub> 30.72&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B38">38</xref>]; orobol 7-<italic>O</italic>-D-glucoside, IC<sub>50</sub> 1.29&#x02013;19.62&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B39">39</xref>]), organic acid (e.g., raoulic acid, IC<sub>50</sub> 0.51&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B40">40</xref>]; gallic acid, IC<sub>50</sub>&#x02009;&#x02248;&#x02009;294.55&#x000a0;&#x003bc;M
[<xref ref-type="bibr" rid="B41">41</xref>]), and thiosulfinates (allicin and allyl methylthiosulfinate
[<xref ref-type="bibr" rid="B42">42</xref>]). It has been reported that HRV capsid-binding compounds toward all HRV serotypes showed the existence of group A and B, based on a wide range of susceptibilities to antiviral compounds
[<xref ref-type="bibr" rid="B43">43</xref>]. In the current study, the antiviral principle was determined to be the tannin ellagic acid. The constituent exhibited antiviral activity toward both group A (HRV-2) and group B (HRV-3 and HRV-4). IC<sub>50</sub> of ellagic acid was between 95.9 and 125.8&#x000a0;&#x003bc;M toward three HRVs, although IC<sub>50</sub> of the natural compounds stated previously is between 0.22 and 294.55&#x000a0;&#x003bc;M. Ellagic acid exhibited greater antiviral activity than ribavirin toward three HRVs and high selectivity. This original finding indicates that materials derived from <italic>L. speciosa</italic> leaves can hold promise for the development of novel and effective naturally occurring antiviral agents for two different HRV groups (A and B). In addition, ellagic acid was reported to possess anti-HIV activity, through inhibition of HIV protease
[<xref ref-type="bibr" rid="B44">44</xref>]. Orobol 7-<italic>O</italic>-D-glucoside from <italic>L. speciosa</italic> leaves is also known to have broad-spectrum antiviral activity toward various HRVs including group A and B, as well as pleconaril-resistant HRV-5
[<xref ref-type="bibr" rid="B39">39</xref>].</p><p>Investigations on the modes of antiviral action of naturally occurring compounds may contribute to the development of selective HRV therapeutic alternatives with novel target sites. The modes of anti-HRV action of plant secondary substances have been well reviewed by Rollinger and Schmidtke
[<xref ref-type="bibr" rid="B45">45</xref>]. Targeting virus molecules is likely more specific and less toxic, but there is a narrow spectrum of viruses and a higher risk of creating resistant viruses
[<xref ref-type="bibr" rid="B46">46</xref>]. On the contrary, chemicals which target cellular molecules may possess a broader antiviral activity spectrum and less risk of developing virus resistance, but may be more toxic to the host cell
[<xref ref-type="bibr" rid="B46">46</xref>]. In the current study, ellagic acid does not interact with the HRV-4 particles, as preexposure of the virus to the constituent did not alter the infectivity of HRV-4 particles. Based on time-of-addition experiments, ellagic acid significantly suppressed HRV-4 infection only when added just after the virus inoculation (0&#x000a0;h), but not before -1&#x000a0;h or after 1&#x000a0;h or later. This finding suggests that ellagic acid may directly interact with the human cells in the early stage of HRV infections to protect the cells from the virus destruction. In addition, RT-PCR analysis revealed that ellagic acid strongly inhibited the RNA replication of HRV-4 in HeLa system, suggesting that ellagic acid inhibit virus replication by targeting on cellular molecules, rather than virus molecules. Detailed tests are needed to fully understand the anti-HRV mode of action of ellagic acid.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p><italic>L. speciosa</italic> leaf-derived preparations containing ellagic acid could be useful as an antiviral agent in the prevention or treatment of HRV infection. The antiviral action of ellagic acid may be an indication of at least one of the pharmacological actions of <italic>L. speciosa</italic>. For the practical use of <italic>L. speciosa</italic> leaf-derived preparations as novel anti-HRV products to proceed, further research is needed to establish their human safety and whether this activity is exerted <italic>in vivo</italic> after consumption of <italic>L. speciosa</italic> leaf-derived products by humans. Historically, a tea from the plant leaves has been used for the treatment of diabetes mellitus in the Philippines
[<xref ref-type="bibr" rid="B28">28</xref>]. Rats fed ellagic acid at doses as high as 50&#x000a0;mg/day up to 45&#x000a0;days did not cause any signs of systemic toxicity
[<xref ref-type="bibr" rid="B47">47</xref>]. Lastly, detailed tests are needed to understand how to improve anti-HRV potency and stability for eventual commercial development.</p></sec><sec><title>Abbreviations</title><p>ATCC: American type culture collection; CC<sub>50</sub>: 50% cytotoxic concentration; CCID<sub>50</sub>: 50% cell culture infective dose; CPE: Cytopathic effect; DMSO: Dimethylsulfoxide; HRV: Human rhinovirus; IC<sub>50</sub>: 50% inhibitory concentration; MEM: Minimum essential medium; PBS: Phosphate-buffered saline; RT-PCR: Reverse transcription-PCR; SRB: Sulforhodamine B; TLC: Thin layer chromatography.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>YJA conceived the project and supervised the study. SWP, MJK, and JYY designed the experimental protocol, carried out the tests, analyzed data, and wrote the first draft of the manuscript. HJC helped to develop the protocol and analyze the data. YJA evaluated the results and wrote the final draft of this manuscript. All of the authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6882/14/171/prepub">http://www.biomedcentral.com/1472-6882/14/171/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgments</title><p>This work was carried out with the support of the Brain Korea 21 PLUS through the National Research Foundation of Korea funded by the Ministry of Education of the Korean Government to Y.-J. Ahn.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Heikkinen</surname><given-names>T</given-names></name><name><surname>Jarvinen</surname><given-names>A</given-names></name><article-title>The common cold</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)12162-9</pub-id><pub-id pub-id-type="pmid">12517470</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Jacobs</surname><given-names>SE</given-names></name><name><surname>Lamson</surname><given-names>DM</given-names></name><name><surname>St George</surname><given-names>K</given-names></name><name><surname>Walsh</surname><given-names>TJ</given-names></name><article-title>Human rhinoviruses</article-title><source>Clin Microbiol Rev</source><year>2013</year><volume>26</volume><fpage>135</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1128/CMR.00077-12</pub-id><pub-id pub-id-type="pmid">23297263</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Pitkaranta</surname><given-names>A</given-names></name><name><surname>Virolainen</surname><given-names>A</given-names></name><name><surname>Jero</surname><given-names>J</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><article-title>Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction</article-title><source>Pediatrics</source><year>1998</year><volume>102</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1542/peds.102.2.291</pub-id><pub-id pub-id-type="pmid">9685428</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Pitkaranta</surname><given-names>A</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name><name><surname>Malmberg</surname><given-names>H</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><article-title>Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR</article-title><source>J Clin Microbiol</source><year>1997</year><volume>35</volume><fpage>1791</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">9196195</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Abzug</surname><given-names>MJ</given-names></name><name><surname>Beam</surname><given-names>AC</given-names></name><name><surname>Gyorkos</surname><given-names>EA</given-names></name><name><surname>Levin</surname><given-names>MJ</given-names></name><article-title>Viral pneumonia in the first month of life</article-title><source>Pediatr Infect Dis J</source><year>1990</year><volume>9</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1097/00006454-199012000-00005</pub-id><pub-id pub-id-type="pmid">2177540</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Duff</surname><given-names>AL</given-names></name><name><surname>Pomeranz</surname><given-names>ES</given-names></name><name><surname>Gelber</surname><given-names>LE</given-names></name><name><surname>Price</surname><given-names>GW</given-names></name><name><surname>Farris</surname><given-names>H</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Platts-Mills</surname><given-names>TA</given-names></name><name><surname>Heymann</surname><given-names>PW</given-names></name><article-title>Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens</article-title><source>Pediatrics</source><year>1993</year><volume>92</volume><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">8414823</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Nicholson</surname><given-names>KG</given-names></name><name><surname>Kent</surname><given-names>J</given-names></name><name><surname>Ireland</surname><given-names>DC</given-names></name><article-title>Respiratory viruses and exacerbations of asthma in adults</article-title><source>British Med J</source><year>1993</year><volume>307</volume><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1136/bmj.307.6910.982</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Rotbart</surname><given-names>HA</given-names></name><article-title>Treatment of picornavirus infections</article-title><source>Antiviral Res</source><year>2002</year><volume>53</volume><fpage>83</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S0166-3542(01)00206-6</pub-id><pub-id pub-id-type="pmid">11750935</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Waterer</surname><given-names>G</given-names></name><name><surname>Wunderink</surname><given-names>R</given-names></name><article-title>Respiratory infections: a current and future threat</article-title><source>Respirology</source><year>2009</year><volume>14</volume><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2009.01554.x</pub-id><pub-id pub-id-type="pmid">19659646</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>RB</given-names></name><article-title>The treatment of rhinovirus infections: progress and potential</article-title><source>Antiviral Res</source><year>2001</year><volume>49</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0166-3542(00)00135-2</pub-id><pub-id pub-id-type="pmid">11166856</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Vlietinck</surname><given-names>AJ</given-names></name><name><surname>Vanden Berghe</surname><given-names>DA</given-names></name><article-title>Can ethnopharmacology contribute to the development of antiviral drugs?</article-title><source>J Ethnopharmacol</source><year>1991</year><volume>32</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(91)90112-Q</pub-id><pub-id pub-id-type="pmid">1652667</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Cowan</surname><given-names>MM</given-names></name><article-title>Plant products as antimicrobial agents</article-title><source>Clin Microbiol Rev</source><year>1999</year><volume>12</volume><fpage>564</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">10515903</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>JE</given-names></name><article-title>Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de Grado</article-title><source>Altern Med Rev</source><year>2001</year><volume>6</volume><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">11804547</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Jassim</surname><given-names>SA</given-names></name><name><surname>Naji</surname><given-names>MA</given-names></name><article-title>Novel antiviral agents: a medicinal plant perspective</article-title><source>J Appl Microbiol</source><year>2003</year><volume>95</volume><fpage>412</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2672.2003.02026.x</pub-id><pub-id pub-id-type="pmid">12911688</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="other"><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><article-title>Management of diabetes and its complications with banaba (<italic>Lagerstroemia speciosa</italic> L.) and corosolic acid</article-title><source>Evid Based Complement Alternat Med</source><year>2012</year><comment>doi:10.1155/2012/871495</comment></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Unno</surname><given-names>T</given-names></name><name><surname>Ushitani</surname><given-names>M</given-names></name><name><surname>Hayasi</surname><given-names>K</given-names></name><name><surname>Kakuda</surname><given-names>T</given-names></name><article-title>Manti obesity activity of extracts from <italic>Lagerstroemia speciosa</italic> L. leaves on female kk-Ay mice</article-title><source>J Nutr Sci Vitaminol</source><year>1999</year><volume>45</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.3177/jnsv.45.791</pub-id><pub-id pub-id-type="pmid">10737232</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Unno</surname><given-names>T</given-names></name><name><surname>Sakane</surname><given-names>I</given-names></name><name><surname>Masumizu</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name><name><surname>Kakuda</surname><given-names>T</given-names></name><article-title>Antioxidative activity of water extracts of <italic>Lagerstroemia speciosa</italic> leaves</article-title><source>Biosci Biotechnol Biochem</source><year>1997</year><volume>61</volume><fpage>1772</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1271/bbb.61.1772</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Unno</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>Kakuda</surname><given-names>T</given-names></name><article-title>Xanthine oxidase inhibitors from leaves of <italic>Lagerstroemia speciosa</italic> (L.) Pers</article-title><source>J Ethnopharmacol</source><year>2004</year><volume>93</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2004.04.012</pub-id><pub-id pub-id-type="pmid">15234783</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Priya</surname><given-names>TT</given-names></name><article-title>Free radical scavenging and anti-inflammatory properties of <italic>Lagerstroemia speciosa</italic></article-title><source>Inflammopharmacology</source><year>2008</year><volume>16</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/s10787-008-7002-6</pub-id><pub-id pub-id-type="pmid">18759076</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Ambujakdhi</surname><given-names>HR</given-names></name><article-title>Antibacterial activity of leaves of <italic>Lagerstroemia speciosa</italic></article-title><source>J Pharm Res</source><year>2009</year><volume>2</volume><fpage>1028</fpage></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Graci</surname><given-names>JD</given-names></name><name><surname>Cameron</surname><given-names>CE</given-names></name><article-title>Mechanisms of action of ribavirin against distinct viruses</article-title><source>Rev Med Virol</source><year>2006</year><volume>16</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/rmv.483</pub-id><pub-id pub-id-type="pmid">16287208</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Vichai</surname><given-names>V</given-names></name><name><surname>Kirtikara</surname><given-names>K</given-names></name><article-title>Sulforhodamine B colorimetric assay for cytotoxicity screening</article-title><source>Nat Protoc</source><year>2006</year><volume>1</volume><fpage>1112</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.179</pub-id><pub-id pub-id-type="pmid">17406391</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Ahn</surname><given-names>YJ</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>DH</given-names></name><article-title>Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus</article-title><source>Antiviral Res</source><year>2009</year><volume>81</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.10.002</pub-id><pub-id pub-id-type="pmid">18992773</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Nawwar</surname><given-names>MAM</given-names></name><name><surname>Souleman</surname><given-names>AMA</given-names></name><article-title>3,4,8,9,10-Pentahydroxy-dibenzo[<italic>b, d</italic>]pyran-6-one from <italic>Tamarix nilotica</italic></article-title><source>Phytochemistry</source><year>1984</year><volume>23</volume><fpage>2966</fpage><lpage>2967</lpage><pub-id pub-id-type="doi">10.1016/0031-9422(84)83057-5</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Chiang</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><article-title><italic>In vitro</italic> antiviral activities of <italic>Caesalpinia pulcherrima</italic> and its related flavonoids</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>52</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg291</pub-id><pub-id pub-id-type="pmid">12837746</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Murakami</surname><given-names>C</given-names></name><name><surname>Myoga</surname><given-names>K</given-names></name><name><surname>Kasai</surname><given-names>R</given-names></name><name><surname>Ohtani</surname><given-names>K</given-names></name><name><surname>Kurokawa</surname><given-names>T</given-names></name><name><surname>Ishibashi</surname><given-names>S</given-names></name><name><surname>Dayrit</surname><given-names>F</given-names></name><name><surname>Padolina</surname><given-names>WG</given-names></name><name><surname>Yamasaki</surname><given-names>K</given-names></name><article-title>Screening of plant constituents for effect on glucose transport activity in Ehrlich ascites tumur cells</article-title><source>Chem Pharm Bull</source><year>1993</year><volume>41</volume><fpage>2129</fpage><lpage>2131</lpage><pub-id pub-id-type="doi">10.1248/cpb.41.2129</pub-id><pub-id pub-id-type="pmid">8118906</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Ragasa</surname><given-names>CY</given-names></name><name><surname>Ngo</surname><given-names>HT</given-names></name><name><surname>Rideout</surname><given-names>JA</given-names></name><article-title>Terpenoids and sterols from <italic>Lagerstroemia speciosa</italic></article-title><source>J Asian Natural Prod Res</source><year>2005</year><volume>7</volume><fpage>71</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1080/10286020310001595999</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="book"><name><surname>Quisumbing</surname><given-names>E</given-names></name><source>Medicinal Plants of the Phillippines</source><year>1978</year><publisher-name>Quezon, the Phillippines: Katha Publishing</publisher-name></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Judy</surname><given-names>WV</given-names></name><name><surname>Hari</surname><given-names>SP</given-names></name><name><surname>Stogsdill</surname><given-names>WW</given-names></name><name><surname>Judy</surname><given-names>JS</given-names></name><name><surname>Naguib</surname><given-names>YMA</given-names></name><name><surname>Passwater</surname><given-names>R</given-names></name><article-title>Antidiabetic activity of a standardized extract (Glucosol&#x02122;) from <italic>Lagerstroemia speciosa</italic> leaves in type II diabetics: a dose-dependence study</article-title><source>J Ethnopharmacol</source><year>2003</year><volume>87</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(03)00122-3</pub-id><pub-id pub-id-type="pmid">12787964</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="book"><name><surname>Liu</surname><given-names>AL</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><person-group person-group-type="editor">Patra AK</person-group><article-title>Antiviral properties of phytochemicals</article-title><source>Dietary Phytochemical and Microbes</source><year>2012</year><publisher-name>New York: Springer</publisher-name><fpage>93</fpage><lpage>126</lpage></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Rollinger</surname><given-names>JM</given-names></name><name><surname>Schuster</surname><given-names>D</given-names></name><name><surname>Danzl</surname><given-names>B</given-names></name><name><surname>Schwaiger</surname><given-names>S</given-names></name><name><surname>Markt</surname><given-names>P</given-names></name><name><surname>Schmidtke</surname><given-names>M</given-names></name><name><surname>Gertsch</surname><given-names>J</given-names></name><name><surname>Raduner</surname><given-names>S</given-names></name><name><surname>Wolber</surname><given-names>G</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Stuppner</surname><given-names>H</given-names></name><article-title>In silico target fishing for rationalized ligand discovery exemplified on constituents of <italic>Ruta graveolens</italic> L</article-title><source>Planta Med</source><year>2009</year><volume>75</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1088397</pub-id><pub-id pub-id-type="pmid">19096995</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Spasova</surname><given-names>M</given-names></name><name><surname>Philipov</surname><given-names>S</given-names></name><name><surname>Nikolaeva-Glomb</surname><given-names>L</given-names></name><name><surname>Galabov</surname><given-names>AS</given-names></name><name><surname>Milkova</surname><given-names>T</given-names></name><article-title>Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities</article-title><source>Bioorg Med Chem</source><year>2008</year><volume>16</volume><fpage>7457</fpage><lpage>7461</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.06.010</pub-id><pub-id pub-id-type="pmid">18590964</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Rollinger</surname><given-names>JM</given-names></name><name><surname>Steindl</surname><given-names>TM</given-names></name><name><surname>Schuster</surname><given-names>D</given-names></name><name><surname>Kirchmair</surname><given-names>J</given-names></name><name><surname>Anrain</surname><given-names>K</given-names></name><name><surname>Ellmerer</surname><given-names>EP</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Stuppner</surname><given-names>H</given-names></name><name><surname>Wutzler</surname><given-names>P</given-names></name><name><surname>Schmidtke</surname><given-names>M</given-names></name><article-title>Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein</article-title><source>J Med Chem</source><year>2008</year><volume>51</volume><fpage>842</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1021/jm701494b</pub-id><pub-id pub-id-type="pmid">18247552</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Ishitsuka</surname><given-names>H</given-names></name><name><surname>Ohsawa</surname><given-names>C</given-names></name><name><surname>Ohiwa</surname><given-names>T</given-names></name><name><surname>Umeda</surname><given-names>I</given-names></name><name><surname>Suhara</surname><given-names>Y</given-names></name><article-title>Antipicornavirus flavone Ro 09&#x02013;0179</article-title><source>Antimicrob Agents Chemother</source><year>1982</year><volume>22</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1128/AAC.22.4.611</pub-id><pub-id pub-id-type="pmid">6295260</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Van Hoof</surname><given-names>L</given-names></name><name><surname>Vanden Berghe</surname><given-names>DA</given-names></name><name><surname>Hatfield</surname><given-names>GM</given-names></name><name><surname>Vlietinck</surname><given-names>AJ</given-names></name><article-title>Plant antiviral agents V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis</article-title><source>Planta Med</source><year>1984</year><volume>50</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1055/s-2007-969786</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Tsuchiya</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Hiyama</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Horie</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>N</given-names></name><article-title>Antiviral activity of natural occurring flavonoids <italic>in vitro</italic></article-title><source>Chem Pharm Bull</source><year>1985</year><volume>33</volume><fpage>3881</fpage><lpage>3886</lpage><pub-id pub-id-type="doi">10.1248/cpb.33.3881</pub-id><pub-id pub-id-type="pmid">4092287</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Semple</surname><given-names>SJ</given-names></name><name><surname>Nobbs</surname><given-names>SF</given-names></name><name><surname>Pyke</surname><given-names>SM</given-names></name><name><surname>Reynolds</surname><given-names>GD</given-names></name><name><surname>Flower</surname><given-names>RL</given-names></name><article-title>Antiviral flavonoid from <italic>Pterocaulon sphacelatum</italic>, an Australian Aboriginal medicine</article-title><source>J Ethnopharmacol</source><year>1999</year><volume>68</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(99)00050-1</pub-id><pub-id pub-id-type="pmid">10624889</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>De Tommasi</surname><given-names>N</given-names></name><name><surname>De Simone</surname><given-names>F</given-names></name><name><surname>Pizza</surname><given-names>C</given-names></name><name><surname>Mahmood</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name><name><surname>Conti</surname><given-names>C</given-names></name><name><surname>Orsi</surname><given-names>N</given-names></name><name><surname>Stein</surname><given-names>ML</given-names></name><article-title>Constituents of <italic>Eriobotrya japonica</italic>: a study of their antiviral properties</article-title><source>J Nat Prod</source><year>1992</year><volume>55</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1021/np50086a006</pub-id><pub-id pub-id-type="pmid">1279126</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Bae</surname><given-names>EY</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>DH</given-names></name><article-title>Inhibitory effects of orobol 7-<italic>O</italic>-D-glucoside from banaba (<italic>Lagerstroemia speciosa</italic> L.) on human rhinovirus replication</article-title><source>Lett Appl Microbiol</source><year>2010</year><volume>51</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20497313</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Lim</surname><given-names>CH</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>DH</given-names></name><article-title>Antiviral activity of raoulic acid from <italic>Raoulia australis</italic> against Picornaviruses</article-title><source>Phytomedicine</source><year>2009</year><volume>16</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2008.10.012</pub-id><pub-id pub-id-type="pmid">19097770</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Bhatt</surname><given-names>LR</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><article-title>Anti-human rhinovirus activity of gallic acid possessing antioxidant capacity</article-title><source>Phytother Res</source><year>2010</year><volume>24</volume><fpage>1292</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1002/ptr.3101</pub-id><pub-id pub-id-type="pmid">20104501</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Weber</surname><given-names>ND</given-names></name><name><surname>Anderson</surname><given-names>DO</given-names></name><name><surname>North</surname><given-names>JA</given-names></name><name><surname>Murray</surname><given-names>BK</given-names></name><name><surname>Lawson</surname><given-names>LD</given-names></name><name><surname>Hughes</surname><given-names>BG</given-names></name><article-title><italic>In vitro</italic> virucidal activity of <italic>Allium sativum</italic> (garlic) extract and compounds</article-title><source>Planta Med</source><year>1992</year><volume>58</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1055/s-2006-961504</pub-id><pub-id pub-id-type="pmid">1470664</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Andries</surname><given-names>K</given-names></name><name><surname>Dewindt</surname><given-names>B</given-names></name><name><surname>Snoeks</surname><given-names>J</given-names></name><name><surname>Wouters</surname><given-names>L</given-names></name><name><surname>Moereels</surname><given-names>H</given-names></name><name><surname>Lewi</surname><given-names>PJ</given-names></name><name><surname>Janssen</surname><given-names>AJ</given-names></name><article-title>Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity</article-title><source>J Virol</source><year>1990</year><volume>64</volume><fpage>1117</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">2154596</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Nutan</surname><given-names>MM</given-names></name><name><surname>Goel</surname><given-names>T</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Suri</surname><given-names>S</given-names></name><name><surname>Rawat</surname><given-names>AKS</given-names></name><name><surname>Srivastava</surname><given-names>SK</given-names></name><name><surname>Tuli</surname><given-names>R</given-names></name><name><surname>Malhotra</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><article-title>Ellagic acid &#x00026; gallic acid from <italic>Lagerstroemia speciosa</italic> L. inhibit HIV-1 infection through inhibition of HIV-1 protease &#x00026; reverse transcriptase activity</article-title><source>Indian J Med Res</source><year>2013</year><volume>137</volume><fpage>540</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">23640562</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Rollinger</surname><given-names>JM</given-names></name><name><surname>Schmidtke</surname><given-names>M</given-names></name><article-title>The human rhinovirus: human pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery</article-title><source>Med Res Rev</source><year>2010</year><volume>31</volume><fpage>42</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19714577</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Kitazato</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><article-title>Viral infectious disease and natural products with antiviral activity</article-title><source>Drug Discov Ther</source><year>2007</year><volume>1</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22504360</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Doyle</surname><given-names>B</given-names></name><name><surname>Griffiths</surname><given-names>LA</given-names></name><article-title>The metabolism of ellagic acid in the rat</article-title><source>Xenobiotica</source><year>1980</year><volume>10</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.3109/00498258009033752</pub-id><pub-id pub-id-type="pmid">7415205</pub-id></mixed-citation></ref></ref-list></back></article>